Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions
Interventions
Zanubrutinib
Ibrutinib
Locations
115
United States
Carti Cancer Center
Little Rock, Arkansas, United States
David Geffen School of Medicine At UCLA
Los Angeles, California, United States
Rocky Mountain Cancer Centers Boulder
Boulder, Colorado, United States
Scri Florida Cancer Specialists South
Fort Myers, Florida, United States
Scri Florida Cancer Specialists North
St. Petersburg, Florida, United States
Augusta University
Augusta, Georgia, United States
Start Date
November 1, 2018
Primary Completion Date
August 8, 2022
Completion Date
February 28, 2024
Last Updated
March 30, 2025
NCT06846671
NCT07218341
NCT06548152
NCT07030400
NCT07277231
NCT05006716
Lead Sponsor
BeiGene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions